CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Equities research analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a research note issued to investors on Wednesday, January 17th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($7.54) per share […]
Sumitomo Mitsui Trust Holdings Inc. reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,465,470 shares of the company’s stock after selling 67,887 shares during the period. Sumitomo […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Hold” from the eighteen research firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating on the company. The […]
ARK Investment Management LLC cut its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,163,118 shares of the company’s stock after selling 175,329 shares during the quarter. CRISPR […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus recommendation of “Hold” from the eighteen brokerages that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. The average […]